Portal Hypertension Management Market Report 2026

The portal hypertension management market size has grown strongly in recent years. It will grow from $3.27 billion in 2025 to $3.49 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increasing prevalence of liver cirrhosis, rising incidence of alcohol-related liver disease, availability of beta-blocker therapies, growing use of endoscopic treatment procedures, expansion of specialized hepatology care.

The portal hypertension management market size is expected to see strong growth in the next few years. It will grow to $4.39 billion in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing demand for advanced liver disease management, rising adoption of t i p s procedures, growing focus on complication prevention, expansion of specialty liver clinics, increasing investment in precision hepatology treatments. Major trends in the forecast period include increasing adoption of minimally invasive treatment approaches, growing use of endoscopic variceal management techniques, rising focus on early intervention strategies, expansion of combination drug therapies, enhanced monitoring of portal pressure levels.

The increasing prevalence of liver diseases is expected to drive the growth of the portal hypertension management market going forward. Liver diseases encompass a range of conditions that impair liver structure or function and are often associated with symptoms such as jaundice, fatigue, and abdominal pain, with causes including viral infections, excessive alcohol consumption, obesity related fatty liver disease, and metabolic disorders. As liver disease progresses, it can lead to portal hypertension, requiring targeted management to lower pressure in the portal vein system. Effective portal hypertension management helps reduce complications such as variceal bleeding, ascites, and hepatic encephalopathy, thereby improving patient outcomes. For instance, in July 2023, according to the World Health Organization, the Western Pacific Region was experiencing a growing burden of liver disease, with an estimated 116 million people living with hepatitis B and 10 million with hepatitis C in 2023. Despite around 3 million new infections each year, low diagnosis and treatment rates continue to contribute to rising cases of liver cirrhosis and liver cancer. Therefore, the increasing prevalence of liver diseases is driving the growth of the portal hypertension management market.

Major companies operating in the portal hypertension management market are increasingly adopting advanced minimally invasive devices to improve treatment effectiveness while reducing procedural risks. Minimally invasive devices are medical tools designed to perform interventions with minimal tissue disruption, often using small incisions or natural access routes. For instance, in November 2023, Medtronic Plc, a US-based medical device manufacturer, received approval from the U.S. Food and Drug Administration for the Symplicity Spyral renal denervation system. This minimally invasive device is used to treat hypertension by applying radiofrequency energy to targeted renal nerves, helping to regulate blood pressure through nerve modulation.

In February 2023, AstraZeneca Plc, a UK-based pharmaceutical company, acquired CinCor Pharma Inc. for $1.8 billion. Through this acquisition, AstraZeneca aimed to strengthen and diversify its cardiorenal and hypertension treatment pipeline by adding barostat (CIN-107), an aldosterone synthase inhibitor developed for lowering blood pressure in patients with treatment resistant hypertension. CinCor Pharma Inc. is a US-based biotechnology company focused on developing therapies for hypertension management.

Major companies operating in the portal hypertension management market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Merck & Co., Boehringer Ingelheim International GmbH, Amneal Pharmaceuticals LLC, Lupin Ltd., Daiichi Sankyo, Dr. Falk Pharma GmbH, Cumberland Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Ipsen Pharma, Eisai Co. Ltd., Johnson & Johnson.

North America was the largest region in the portal hypertension management market in 2025. The regions covered in the portal hypertension management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the portal hypertension management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the portal hypertension management market by increasing costs of imported medical devices, endoscopic equipment, imaging tools, and specialized surgical instruments used in diagnostic and interventional procedures. Hospitals and specialty clinics in North America and Europe are most affected due to reliance on imported equipment, while Asia-Pacific faces increased procedural costs. These tariffs are contributing to higher treatment expenses and delayed technology upgrades. However, they are also encouraging domestic device manufacturing, localized supply chains, and broader adoption of cost-effective therapeutic solutions.

The portal hypertension management market research report is one of a series of new reports that provides portal hypertension management market statistics, including portal hypertension management industry global market size, regional shares, competitors with a portal hypertension management market share, detailed portal hypertension management market segments, market trends and opportunities, and any further data you may need to thrive in the portal hypertension management industry. This portal hypertension management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Portal hypertension management involves the treatment and prevention of complications caused by elevated pressure in the portal vein system, most commonly resulting from liver cirrhosis. Management focuses on lowering portal pressure through approaches such as lifestyle modifications, pharmacological therapies including beta blockers, and interventional procedures such as variceal band ligation to prevent or control complications like variceal bleeding and ascites.

The primary approaches to portal hypertension management include medication, non surgical procedures, and surgical interventions. Medications used for portal hypertension typically include nonselective beta blockers, vasoconstrictors, diuretics, and antibiotics, which help manage complications such as variceal bleeding, fluid accumulation, and infections associated with increased portal pressure. Procedural options include transjugular intrahepatic portosystemic shunt (TIPS), and these treatments are utilized by various end users such as hospitals, specialty clinics, and others.

The portal hypertension management market consists of revenues earned by entities by provide services such as medical management, endoscopic therapy, interventional radiology procedures, and monitoring and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The portal hypertension management market also includes sales of nonselective beta-blockers, and vasoconstrictors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.